Dato-DXd showed a 43% reduction in disease progression risk and a 21% reduction in death risk compared to chemotherapy in TNBC patients ineligible for immunotherapy. The TROPION-Breast02 trial ...

Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of ...

The perioperative enfortumab vedotin plus pembrolizumab (EV-P) substantially increased the frequency of adverse events (AEs), ...

Falling Fed rates and favorable policies make XLV a strong healthcare ETF pick. Read here for an analysis of its growth ...

Alectinib showed a 22% reduction in death risk compared to crizotinib in advanced ALK-positive NSCLC, with a median OS of 81.1 months versus 54.2 months. Significant OS benefits were observed in ...

Merck MRK is facing persistent challenges for its second-largest product, Gardasil, which is a vaccine for the prevention of ...

This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around ...

The moves, to lower the cost of a drug prescribed to women going through IVF and boost employer coverage, follow Trump’s campaign promise to make fertility care more accessible.

The Trump administration has struck a deal with EMD Serono to lower drug prices — part of a larger push from the ...

According to a Securities and Exchange Commission (SEC) filing dated October 16, 2025, ASSET PLANNING SERVICES INC /LA/ /ADV ...

Findings point to importance of RSV vaccination in older patients with systemic autoimmune rheumatic diseases.

OPKO Health, Inc. is refocusing on drug development, selling BioReference Lab assets to strengthen its balance sheet. Learn ...